Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
|Articles|December 13, 2016
Effect of Adjuvant Chemo on Elderly Patients’ Quality of Life
Author(s)Bobby Lazzara, MD
In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.
Advertisement
In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.
Advertisement
Related to this article
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
2
Closing the Gaps in Precision Oncology for Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5